Spark Therapeutics Inc (ONCE) Shares Bought by Bailard Inc.

Bailard Inc. raised its position in Spark Therapeutics Inc (NASDAQ:ONCE) by 35.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 55,155 shares of the biotechnology company’s stock after purchasing an additional 14,555 shares during the quarter. Bailard Inc. owned 0.15% of Spark Therapeutics worth $2,836,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Ameritas Investment Partners Inc. increased its position in shares of Spark Therapeutics by 23.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 389 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of Spark Therapeutics during the second quarter worth $143,000. Teacher Retirement System of Texas purchased a new stake in shares of Spark Therapeutics during the third quarter worth $225,000. Prudential Financial Inc. purchased a new stake in shares of Spark Therapeutics during the third quarter worth $239,000. Finally, Commonwealth Equity Services Inc purchased a new stake in shares of Spark Therapeutics during the third quarter worth $257,000. 95.87% of the stock is currently owned by institutional investors.

Spark Therapeutics Inc (NASDAQ ONCE) opened at $54.11 on Thursday. Spark Therapeutics Inc has a 12 month low of $41.06 and a 12 month high of $91.75.

In other Spark Therapeutics news, insider Katherine A. High sold 5,000 shares of the company’s stock in a transaction on Tuesday, November 28th. The shares were sold at an average price of $71.32, for a total value of $356,600.00. Following the completion of the transaction, the insider now owns 215,000 shares in the company, valued at $15,333,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 7.30% of the company’s stock.

A number of analysts have recently weighed in on ONCE shares. Royal Bank of Canada reaffirmed a “buy” rating on shares of Spark Therapeutics in a research report on Wednesday, October 25th. ValuEngine lowered Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. BMO Capital Markets reissued a “buy” rating and issued a $101.00 target price on shares of Spark Therapeutics in a report on Wednesday, November 15th. Raymond James Financial reissued a “buy” rating and issued a $75.00 target price on shares of Spark Therapeutics in a report on Thursday, December 7th. Finally, Cantor Fitzgerald set a $105.00 target price on Spark Therapeutics and gave the company a “buy” rating in a report on Monday, December 11th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and seventeen have given a buy rating to the company. Spark Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $72.63.

COPYRIGHT VIOLATION WARNING: This story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://ledgergazette.com/2018/02/15/spark-therapeutics-inc-once-shares-bought-by-bailard-inc.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply